We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

53 hedge funds and large institutions have $928K invested in BRAINSTORM CELL THERAPUTC in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 12

0.47% less ownership

Funds ownership: 1.18% → 0.71% (-0.47%)

9% less funds holding

Funds holding: 58 → 53 (-5)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

83% less call options, than puts

Call options by funds: $149K | Put options by funds: $888K

93% less capital invested

Capital invested by funds: $14.1M → $928K (-$13.1M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
53
Holders Change
-5
Holders Change %
-8.62%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
8
Increased
15
Reduced
12
Closed
12
Calls
$149K
Puts
$888K
Net Calls
-$739K
Net Calls Change
-$896K

Top Buyers

Rank Fund Capital Flow
1
GS
GTS Securities
New York
+$307K
2
LWM
Liberty Wealth Management
California
+$306K
3
Group One Trading
Group One Trading
Illinois
+$147K
4
TSS
Two Sigma Securities
New York
+$61K
5
Millennium Management
Millennium Management
New York
+$57.5K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.71M
2
ACM
AIGH Capital Management
Maryland
-$1.46M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$767K
4
WVP
Worth Venture Partners
New Jersey
-$362K
5
AHB
Abner Herrman & Brock
New Jersey
-$204K
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
26
XTX Topco
Cayman Islands
$4.9K +$37.1K +1,633 New
Janney Montgomery Scott
27
Janney Montgomery Scott
Pennsylvania
$4K – – –
PFA
28
Professional Financial Advisors
Nebraska
$3.46K – – –
Creative Planning
29
Creative Planning
Kansas
$3.23K – – –
Osaic Holdings
30
Osaic Holdings
Arizona
$3K +$6.43K +283 +40%
AWM
31
AE Wealth Management
Kansas
$2.89K +$21.9K +961 New
AWM
32
Avior Wealth Management
Nebraska
$2.54K – – –
SFG
33
Socha Financial Group
New York
$2.48K – – –
CWA
34
Centennial Wealth Advisory
Michigan
$2.4K +$18.2K +800 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$2.4K – – –
Charles Schwab
36
Charles Schwab
California
$2.26K – – –
HighTower Advisors
37
HighTower Advisors
Illinois
$2K +$15.9K +698 New
IFAM
38
Institutional & Family Asset Management
Colorado
$1.2K +$4.55K +200 +100%
SPIA
39
Steward Partners Investment Advisory
New York
$1.04K -$4.55K -200 -37%
BSB
40
Bangor Savings Bank
Maine
$800 – – –
UBS Group
41
UBS Group
Switzerland
$728 +$1.73K +76 +46%
CCMW
42
Cypress Capital Management (Wyoming)
Wyoming
$600 +$3.02K +133 +199%
WT
43
Washington Trust
Rhode Island
$500 – – –
VAG
44
VisionPoint Advisory Group
Texas
$389 – – –
Bank of America
45
Bank of America
North Carolina
$200 -$6.32K -278 -81%
HI
46
Harbour Investments
Wisconsin
$159 -$1.02K -45 -46%
DJSG
47
D.J. St. Germain
Massachusetts
$100 – – –
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$73 – – –
WIM
49
Westside Investment Management
California
$40 – – –
MSFP
50
Mark Sheptoff Financial Planning
Connecticut
$20 – – –
1
2
3

BCLI Hedge Fund Activity: Q3 2023 in Review

53 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2023, worth a combined $928K — down 93% from $14.1M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of BCLI and 8 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 15 added.

The largest buyer was GTS Securities, opening a new position worth an estimated $307K. The largest seller was Sabby Management, cutting an estimated $1.71M.

  • 53 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2023, down from 58 in Q2 2023.
  • Funds reported $928K of BRAINSTORM CELL THERAPUTC stock for Q3 2023, down 93% quarter-over-quarter.
  • 8 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2023 and 12 closed out, a net change of -4 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2023 was GTS Securities, an estimated $307K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q3 2023 was Sabby Management, an estimated $1.71M sold.

Based on aggregated 13F filings for Q3 2023.